10-Q: Alkermes Reports Q2 2024 Results: Revenue Mixed Amidst Strategic Shifts

Alkermes' Q2 2024 results show a decrease in manufacturing and royalty revenue offset by an increase in product sales, alongside strategic moves including the sale of the Athlone facility.

Summary

• Alkermes reported a net income from continuing operations of $94.7 million for the three months ended June 30, 2024, a decrease compared to $279.1 million for the same period in 2023.
• For the six months ended June 30, 2024, net income from continuing operations was $133.6 million, down from $267.1 million in the first half of 2023.
• The decline in net income was primarily due to a significant decrease in manufacturing and royalty revenues, which fell by $256.1 million in Q2 and $212.1 million in the first half of 2024.
• This decrease was partially offset by an increase in product sales, which rose by $37.8 million in Q2 and $56.6 million in the first half of 2024.
• Operating expenses decreased by $46.9 million in Q2 and $38.4 million in the first half of 2024, contributing to the offset.
• The company completed the sale of its Athlone manufacturing facility to Novo Nordisk on May 1, 2024, receiving approximately $97.9 million.
• Alkermes entered into subcontracting arrangements with Novo to continue certain manufacturing activities at the Athlone facility through 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While product sales are growing and operating expenses are down, the significant drop in royalty revenue and the upcoming loss of INVEGA SUSTENNA royalties are concerning. The company is making strategic moves, but the financial results are weaker than the previous year.

Positives

• Product sales, particularly for LYBALVI, showed strong growth.
• Operating expenses were reduced, contributing to profitability.
• The sale of the Athlone facility generated a significant cash inflow of $97.9 million.
• The company has a share repurchase program in place, indicating confidence in its future prospects.
• The company is advancing its ALKS 2680 development program for narcolepsy, with phase 2 studies expected to begin in the third quarter of 2024.

Negatives

• Manufacturing and royalty revenues experienced a substantial decrease due to the one-time receipt of back royalties in the prior year.
• The expected end of royalty revenues from INVEGA SUSTENNA in August 2024 will negatively impact future revenues.
• The company is facing Paragraph IV litigation related to INVEGA SUSTENNA and INVEGA TRINZA, which could lead to increased competition and pricing pressure.
• Net income from continuing operations decreased significantly compared to the same periods in the previous year.

Risks

• The company faces risks related to the loss of royalty revenue from INVEGA SUSTENNA.
• Ongoing litigation related to INVEGA products and VUMERITY could impact future revenues and profitability.
• The company's reliance on third-party manufacturing and royalty agreements exposes it to risks related to those partnerships.
• The success of the ALKS 2680 development program is subject to the risks inherent in drug development.
• The company's financial performance is subject to fluctuations in currency exchange rates.

Future Outlook

Alkermes expects royalty revenues from net sales of the long-acting INVEGA products to decrease in the near-term, as the royalty revenues related to net sales of INVEGA SUSTENNA are expected to end on August 20, 2024. The company also anticipates initiating a phase 2 study for ALKS 2680 in patients with narcolepsy type 2 in the third quarter of 2024.

Management Comments

• Management noted that the decrease in manufacturing and royalty revenues was primarily due to the receipt of back royalties in June 2023.
• Management highlighted the strong growth in LYBALVI product sales.
• Management stated that the company is focused on advancing its ALKS 2680 development program.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and competition from both branded and generic products. Alkermes' strategic shift, including the sale of its manufacturing facility and focus on neuroscience, reflects a broader trend in the industry towards specialization and asset optimization. The company's reliance on partnerships and licensing agreements is also a common practice in the industry, allowing companies to leverage external expertise and resources.

Comparison to Industry Standards

• Alkermes' revenue mix, with a combination of proprietary product sales and royalty income, is typical of mid-sized biopharmaceutical companies.
• The company's R&D spending, while significant, is in line with industry averages for companies developing novel therapeutics.
• The decrease in manufacturing and royalty revenue due to the one-time payment is not unusual, as many companies experience fluctuations in revenue due to milestone payments or patent expirations.
• The company's focus on neuroscience is a growing area of interest in the industry, with several companies investing heavily in this space.
• The company's share repurchase program is a common practice among publicly traded companies, indicating confidence in future performance.
• The company's legal challenges related to patent infringement are also common in the industry, particularly for companies with branded products.

Legal Proceedings

• Janssen Pharmaceutica and Janssen Pharmaceuticals, Inc. initiated patent infringement lawsuits against Teva, Mylan, Pharmascience, Accord, and Qilu related to INVEGA SUSTENNA.
• Janssen Pharmaceutica, Janssen Pharmaceuticals, Inc., and Janssen Research & Development, LLC initiated a patent infringement lawsuit against Mylan related to INVEGA TRINZA.
• Biogen Inc., Biogen Swiss Manufacturing GmbH and Alkermes Pharma Ireland Limited filed a patent infringement lawsuit against Zydus related to VUMERITY.
• The company is involved in a product liability case alleging that the FDA-approved VIVITROL labeling was inadequate.
• The company has received a subpoena and civil investigative demands from U.S. state and federal governmental authorities for documents related to VIVITROL.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the expected loss of INVEGA SUSTENNA royalties.
• Employees may be affected by the company's strategic shifts and cost-cutting measures.
• Customers may benefit from the company's continued focus on developing innovative medicines.
• Suppliers may be impacted by the company's sale of the Athlone facility and changes in manufacturing arrangements.
• Creditors may be impacted by the company's debt levels and financial performance.

Next Steps

• The company expects to initiate Vibrance-2, a phase 2 study in patients with narcolepsy type 2, in the third quarter of 2024.
• The company will continue to monitor the impact of the end of INVEGA SUSTENNA royalties on its financial performance.
• The company will continue to defend its intellectual property in ongoing litigation.

Key Dates

Keywords

Alkermes, biopharmaceutical, neuroscience, LYBALVI, VIVITROL, ARISTADA, INVEGA, VUMERITY, ALKS 2680, royalty revenue, product sales, manufacturing, clinical trials, share repurchase, Athlone facility